Answers are grounded in this paper and cite their sources.
In vivo findings demonstrate that polysaccharides alleviate ulcerative colitis symptoms, improving gut microbiota and inflammatory cytokines.
The treatment of ulcerative colitis (UC) remains a clinical challenge due to its frequent recurrence, underscoring the urgent need for novel functional food-based therapeutic strategies. In this study, a polysaccharide (ATP-W-1) was isolated from Asimina triloba fruit, structurally characterized, and evaluated for its therapeutic efficiency in a DSS-induced UC mouse model. ATP-W-1, with a molecular weight of 164,504 g/mol, was composed of mannose, rhamnose, glucose, galactose, and arabinose. In vivo study revealed that ATP-W-1 significantly ameliorated UC symptoms by preventing body weight loss and modulating inflammatory cytokines (IL-6, IL-10, and TNF-α) expression. Specifically, it downregulated IL-6 and TNF-α associated with the NF-κB pathway and restoration of epithelial barrier integrity, as evidenced by increased expression of tight junction proteins (Claudin 1, ZO-1, and Occludin). Furthermore, ATP-W-1 positively modulated the gut microbiota composition and enhanced the prodcution of short-chain fatty acids (SCFAs), thereby contributing to the reestablishment of intestinal homeostasis. Collectively, these findings highlight that ATP-W-1 is a promising functional food ingredient with therapeutic potential for UC prevention and management.
No takes yet. Share an insight, caveat, or question.
LI et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: